莱索托接受过治疗的人HIV感染者中出现的获得性多替拉韦耐药
该研究在莱索托东北部病毒载量队列的常规诊疗中评估多替拉韦耐药的出现。在15349名从非核苷类逆转录酶抑制剂方案转换为多替拉韦方案且转换前后均有病毒载量检测的成人和儿童中,157人(1.0%)符合病毒学标准,85人(0.6%)基因型耐药检测成功,其中8人(9.4%)存在多替拉韦耐药。作者结论认为,在转换为多替拉韦方案≥18个月后持续或反复病毒血症者中约9%存在多替拉韦耐药,非洲需应对获得性多替拉韦耐药的检测与管理。
要点
- 15349名转换方案者中157人(1.0%)符合病毒学标准,85人(0.6%)耐药检测成功。
- 85人中8人(9.4%)有多替拉韦耐药,其中2人(2.4%)预测为中度、6人(7.1%)为高度耐药。
- 8人中1人方案含2种、2人含1种、5人含0种活性药物;转换前有检测的5人中4人含0种、1人含1种活性药物。
核心结论
- 在转换为多替拉韦方案≥18个月后持续或反复HIV病毒血症者中,约9%存在多替拉韦耐药。
- 作者认为,非洲各地必须解决获得性多替拉韦耐药的检测与管理问题。
研究设计与样本
- 研究在莱索托东北部病毒载量队列的常规诊疗中评估多替拉韦耐药的出现。
- 纳入从非核苷类逆转录酶抑制剂方案转换为多替拉韦方案、且转换前后至少各有1次病毒载量检测的成人和儿童参与者。
- 对符合额外病毒学标准者(服用多替拉韦期间有2次病毒血症、其中至少1次病毒载量≥500拷贝/mL且距转换≥18个月)的可用样本进行测序。
主要发现
- 15349名参与者中157人(1.0%)符合病毒学标准,85人(0.6%)基因型耐药检测成功。
- 85人中8人(9.4%)存在多替拉韦耐药,其中2人(2.4%)预测为中度耐药、6人(7.1%)预测为高度耐药。
- 这8人中1人方案含2种活性药物、2人含1种、5人含0种。
- 8人中5人有转换前的基因型耐药检测结果:4人非核苷类逆转录酶抑制剂方案含0种活性药物、1人含1种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since 2019, the World Health Organization has recommended dolutegravir-based antiretroviral therapy (ART) as the preferred regimen for human immunodeficiency virus management. Large-scale programmatic transitioning to dolutegravir-based ART was subsequently implemented across Africa, often in the absence of recent viral load testing and without access to genotypic resistance testing (GRT) in case of viremia. METHODS: This study assessed emerging dolutegravir resistance in the routine care of the Viral Load Cohort North-East Lesotho. We included pediatric and adult participants who changed from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based ART and had at least 1 viral load assessment before and after the change. We sequenced available samples of participants fulfilling the additional virological criteria of having 2 viremic episodes while taking dolutegravir, with at least 1 viral load ≥500 copies/mL taken ≥18 months after changing to dolutegravir. RESULTS: Among 15 349 participants, 157 (1.0%) met the virological criteria, and GRT was successful for 85 (0.6%). Among these 85, 8 (9.4%) had dolutegravir resistance, with 2 (2.4%) and 6 (7.1%) predicted to have intermediate- and high-level dolutegravir resistance, respectively. One participant had 2, 2 had 1, and 5 had 0 active drugs in their regimen. A GRT from before the change to dolutegravir was available for 5 of these 8 participants: 4 had 0 and 1 had 1 active drug in their nonnucleoside transcriptase inhibitor-based regimen. CONCLUSIONS: Nine percent of people with persistent or recurring human immunodeficiency virus viremia ≥18 months after changing to dolutegravir-based ART had dolutegravir resistance. Detection and management of emerging dolutegravir resistance must be addressed across Africa.
引用
- Tschumi N, Lukau B, Tlali K, et al. Emergence of Acquired Dolutegravir Resistance in Treatment-experienced People With HIV in Lesotho. Clin Infect Dis. 2024. PMID: 38567806. doi:10.1093/cid/ciae185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。